ArticleACS omega2025
Multibatch Fingerprint Integrated with Multi-Indicator Efficacy for Quality Evaluation of Sanhua Decoction and Investigation of Its Mechanistic Basis against Cerebral Ischemia-Reperfusion Injury.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Building upon the spectrum-effect relationship theory in traditional Chinese medicine, ultraperformance liquid chromatography (UPLC) was utilized to generate fingerprint profiles for 12 batches of Sanhua Decoction (SHD). These profiles were analyzed in relation to pharmacological efficacy, providing a novel strategy to elucidate the material basis of SHD against cerebral ischemia-reperfusion injury (CIRI) and for efficacy evaluation. The UPLC fingerprints identified 33 common peaks, with 28 chemical constituents characterized. Pharmacodynamic assessment using a rat CIRI model demonstrated that SHD significantly improved neurological deficit scores, reduced cerebral infarct volume, and enhanced brain histopathology, with effects correlated to key indicators such as vascular endothelial growth factor. Gray relational analysis showed that 32 of the 33 peaks had a correlation degree greater than 0.706 with efficacy, confirming the synergistic effect of multiple components in SHD's anti-CIRI action. Orthogonal partial least-squares discriminant analysis identified 11 potential major active compounds significantly associated with anti-CIRI activity. An "efficacy-integrated fingerprint" was constructed by integrating chemical fingerprinting with pharmacodynamic indices, reflecting the intrinsic quality of SHD. This methodology offers a scientific and efficient approach for chemical constituent investigation and pharmacodynamic material basis elucidation of SHD and other traditional Chinese medicines.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.